NCT02143466 2026-01-30AZD9291 in Combination With Ascending Doses of Novel TherapeuticsAstraZenecaPhase 1 Active not recruiting344 enrolled
NCT03392246 2026-01-22A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerDana-Farber Cancer InstitutePhase 2 Active not recruiting25 enrolled